mynth
← DATABASE
10/2018MajorityLBO

Bridgepoint takes majority stake in HTL Biotechnology

FRANCE Life Sciences / Pharma & Biotech / CDMO EV €500M–1.5bn

Context

Bridgepoint has acquired a majority stake in HTL, the specialized producer of hyaluronic acid, in a secondary LBO transaction from Naxicap Partners. This operation follows a period of rapid development under the previous sponsor, which had orchestrated a management buy-in (MBI) only eighteen months prior. In this new capital structure, Naxicap Partners retains a significant minority interest, signaling continued confidence in the company's growth trajectory and industrial potential. The rationale for the transaction is rooted in HTL,s exceptional profitability and its unique position in a high-barrier-to-entry niche of the biotechnology sector. With Bridgepoint,s support, HTL aims to accelerate its international transformation, moving beyond its historical European stronghold to capture market share in North America and Asia.

The acquisition of HTL Biotechnology is part of the growth strategy of Bridgepoint, which already has several external growth operations under its belt, notably Zenith in 2017.

HTL Biotechnology, which reported an EBITDA margin of [members only] in 2018, is valued in this transaction at an EV/EBITDA multiple of 15x–25x.

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in the late 20th century, HTL is a leading global biotechnology company specializing in the development, production, and purification of pharmaceutical-grade hyaluronic acid and other bio-sourced polymers. Based in Brittany, the company utilizes advanced fermentation and purification processes to supply high-purity ingredients to the global healthcare industry. Its value proposition is centered on technical excellence and the ability to provide customized molecular weights for sensitive medical applications, including dermatology for wrinkle filling, ophthalmology for cataract surgery, and rheumatology for joint treatments. HTL,s strategy focuses on continuous innovation through significant R&D investments and the expansion of its industrial capacities to maintain a leadership position in the high-end biopolymer market. By maintaining a discreet but critical role in the pharmaceutical supply chain, the company ensures that global medical device and pharma manufacturers have access to safe, natural, and highly effective components for life-changing medical treatments.

Ent. Value

€500M–1.5bn

Equity Value

[members only]

Multiples

EV / Revenue

Above 6x

EV / EBITDA

15x–25x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2018
€50–100M
€25–50M
[members only]
2017
€50–100M
€25–50M
[members only]

Other operations with HTL Biotechnology

Other operations with HTL Biotechnology
DateAcquirerTargetCountrySector
02/2022MONTAGU PRIVATE EQUITY / PARTNERS GROUPHTL BIOTECHNOLOGYFRANCECDMO

Other operations with Bridgepoint

Other operations with Bridgepoint
DateAcquirerTargetCountrySector
05/2020BRIDGEPOINTKEREISFRANCEBrokerage
01/2019BRIDGEPOINTMIYA WATERSPAINWater
01/2017BRIDGEPOINTZENITHUNITED KINGDOMFleet Management Finance
12/2016BRIDGEPOINTROVENSAPORTUGALSpecialty Chemicals
11/2016BRIDGEPOINTVITAMIN WELLSWEDENSoft Drinks
06/2016BRIDGEPOINT / RAISE / FLEXSTONE PARTNERSACTEONFRANCEMedical Devices
12/2015BRIDGEPOINTELEMENT MATERIALS TECHNOLOGYUNITED KINGDOMTIC (Testing, Inspection, Certification)
01/2015BRIDGEPOINTEFRONTFRANCEFinancial Services / Banking
12/2014BRIDGEPOINTAZZURRI GROUPUNITED KINGDOMRestaurants / Chains
05/2013BRIDGEPOINTFLEXITALLIC GROUPUNITED STATESComponents

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
12/2018MERCK & CO.ANTELLIQFRANCEAnimal Health
11/2018ARDIANNEOPHARMED GENTILIITALYGenerics / Labs
10/2018ARDIANINULA GROUPBELGIUMPharma & Biotech
10/2018ASTORGNEMERAFRANCEMedical Consumables
10/2018GLANBIASLIMFASTUNITED STATESNutrition & Dietary Supplements
08/2018DENTRESSANGLEACTEONFRANCEMedical Devices
05/2018PERMIRACORIN GROUPUNITED KINGDOMImplants & Prosthetics
05/2018ZOETISABAXISUNITED STATESDiagnostic Equipment
05/2018NNPARAGON MEDICALUNITED STATESMedical Devices
12/2017PERKINELMEREUROIMMUN MEDICAL LABORATORY DIAGNOSTICSGERMANYDiagnostic Equipment

REFERENCES

Valuation range: EV €500M–1.5bn

Revenue range: €50–100M

EBITDA range: €25–50M

EV/Revenue range: Above 6x

EV/EBITDA range: 15x - 25x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of HTL Biotechnology by Bridgepoint are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: htl biotechnology

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in HTL Biotechnology, a French company specialised in Pharma & Biotech, by Bridgepoint in 2018, structured as a leveraged buyout (LBO). Ownership has since evolved, leading to a subsequent transaction with Montagu Private Equity / Partners Group in February 2022 (see the dedicated deal page for details).

How was the acquisition of HTL Biotechnology by Bridgepoint valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €500M–1.5bn band, its EV/EBITDA multiple within the 15x - 25x range, and its EV/revenue multiple within the Above 6x range. Exact figures are available to members.

What were HTL Biotechnology’s revenue and EBITDA at the time of the deal?

At the time of the transaction, HTL Biotechnology generated annual revenue estimated in the €50–100M range and EBITDA in the €25–50M bracket (FY 2018). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction intelligence is supported by independent reporting from specialized financial publications, alongside a private document shared by the community and verified by the mynth team to ensure the accuracy of the shared information.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.